Pathways To Access & Reimbursement

Offering a critical analysis of Canada’s access and reimbursement environment, and in-depth discussions on how to adapt market access strategies — especially at a time when affordability and overall health system sustainability are top of mind.

This Year’s Highlights

• The impact of the pandemic on CADTH reviews and pCPA negotiations, and how to mitigate time-to-market delays
• Cell and Gene Therapy: How to secure public/private payer reimbursement for these potentially life-changing but high-cost therapies
• How to attract and retain top-notch talent to Canada’s life sciences sector amid shifting public policy
• Data and AI: How to obtain, analyze, and utilize health outcome data to empower decision-making from clinical trials to reimbursement and beyond

Practitioners at every level with experience in:

• Pricing
• Reimbursement
• Market access
• Patient access
• Government and regulatory affairs
• Health economics
• Research and development
• Policy and compliance
• Pharmacy services
• Marketing
• National trade
• Formularies
• Business development
• Sales

About this Conference

The COVID-19 pandemic has exacerbated time and budgetary constraints leaving market access strategies in a precarious place. At the same time, the National Pharmacare program and PMPRB reforms continue to unfold slowly, with many questions yet to be answered about how these pieces will form a cohesive approach to improved access and affordability without sacrificing innovation.

This annual forum will host critical conversations, examining the most vexing questions and challenges hovering over manufacturers, payers, and patient groups alike, while also exploring opportunities to empower decision-making so that the right treatment reaches patients at the right time.

Join us at this highly anticipated market access event to share best practices, participate in candid discussions, and hear the latest developments from leading drug manufacturers and other industry leaders.